1-3 of 3
Ara Metjian
Close
Sort by
Journal Articles

A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry

Mouhamed Yazan Abou-Ismail, Chong Zhang, Angela P. Presson, Shruti Chaturvedi, Ana G. Antun, Andrew M. Farland, Ryan Woods, Ara Metjian, Yara A. Park, Gustaaf de Ridder, Briana Gibson, Raj S. Kasthuri, Darla K. Liles, Frank Akwaa, Todd Clover, Lisa Baumann Kreuziger, Meera Sridharan, Ronald S. Go, Keith R. McCrae, Harsh Vardhan Upreti, Radhika Gangaraju, Nicole K. Kocher, X. Long Zheng, Jay S. Raval, Camila Masias, Spero R. Cataland, Andrew D. Johnson, Elizabeth Davis, Michael D. Evans, Marshall Mazepa, Ming Y. Lim
Journal: Blood Advances
Blood Adv (2024) 8 (3): 620–623.
https://doi.org/10.1182/bloodadvances.2023010807
Published: 2024
Includes: Supplemental data
Journal Articles

C5 inhibition allows continued antineoplastic therapy in cancer- and chemotherapy-associated thrombotic microangiopathy

Clinical Trials & Observations
Hridaya Shah, Hang Chen, Xiang-Zuo Pan, Ara Metjian, Robert A. Brodsky, Evan M. Braunstein, Shruti Chaturvedi
Journal: Blood Advances
Blood Adv (2022) 6 (23): 6071–6074.
https://doi.org/10.1182/bloodadvances.2022008395
Published: 2022
Includes: Supplemental data
Journal Articles

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Clinical Trials & Observations
Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Hilde De Winter, Filip Callewaert
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2137–2141.
https://doi.org/10.1182/bloodadvances.2020001834
Published: 2021
Includes: Supplemental data